Breast Cancer Clinical Trial

IFACT: Incidental Findings in Advanced Cancer Therapy

Summary

The proposed study, IFACT - Incidental Findings in Advanced Cancer Therapy, will address this research gap by examining MSK patients' attitudes, preferences, and information needs regarding incidental findings arising from tumor genomic profiling.

View Full Description

Full Description

Part 1, the investigators will recruit 40 participants from those already enrolled in existing MSK IRB protocol #12-245 (PI: David Hyman, MD) including male and female patients who have been diagnosed with late-stage breast, colorectal, bladder, and lung cancer (some of the most common cancers in this study population).

Part 2, the investigators will recruit 20 participants from those who have actually received incidental germline findings from MSK IRB protocol #12-245 Consent Part C in order to cognitively test novel survey items about their knowledge and perceived utility of their incidental findings (note that the content of these items will be derived from the data collected in Part 1)

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Part 1:

Patient enrolled on MSK protocol #12-245
Living patient age 18 or older
Patient diagnosed with breast cancer, colorectal cancer, bladder cancer, or lung cancer
Patient residing in New York metro-area

Part 2:

Living patient age 18 or older
Consented to Part C of IRB#12-245 and has received results regardless if thereir was a pathogenic variant
Patient diagnosed with cancer type approved for IRB#12-245 Part C (which are currently breast cancer, gynecological cancer, prostate cancer, and GU non-prostate cancer)breast cancer, colorectal cancer, bladder cancer, or lung cancer
Patient residing in New York metro-area

Exclusion Criteria for Part 1 and 2:

Non-English speakers because we do not have the resources to conduct and translate the interviews into other languages.
Patient unwilling or unable to provide informed consent.

Study is for people with:

Breast Cancer

Estimated Enrollment:

60

Study ID:

NCT02217891

Recruitment Status:

Completed

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

60

Study ID:

NCT02217891

Recruitment Status:

Completed

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider